Media headlines about Merrimack Pharmaceuticals (NASDAQ:MACK) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 49.0249286792687 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern’s scoring:
- Wired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non … – Digital Journal (digitaljournal.com)
- Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 – Nasdaq (nasdaq.com)
- Merrimack Provides Business Update and Reports 2017 Financial Results – PR Newswire (press release) (prnewswire.com)
- BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer (reuters.com)
- Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer (finance.yahoo.com)
Shares of Merrimack Pharmaceuticals (MACK) traded up $0.05 during midday trading on Wednesday, hitting $10.27. The stock had a trading volume of 131,756 shares, compared to its average volume of 129,747. Merrimack Pharmaceuticals has a 12-month low of $9.68 and a 12-month high of $39.90. The stock has a market cap of $138.63, a P/E ratio of 0.29 and a beta of 1.59. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.35 and a quick ratio of 3.35.
COPYRIGHT VIOLATION NOTICE: “Merrimack Pharmaceuticals (MACK) Receiving Somewhat Positive Press Coverage, Report Finds” was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-merrimack-pharmaceuticals-mack-stock-price/1925891.html.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.